Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $75.65 | Total: $378.25 |
| 1 | 10 | $64.08 | Total: $640.80 |
| 1 | 25 | $54.29 | Total: $1,357.25 |
| 1 | 50 | $46.28 | Total: $2,314.00 |
| 1 | 100 | $40.05 | Total: $4,005.00 |
Overview
XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.
Chemical Properties
| Molecular Formula | C36H39ClFN7O2 |
| Molecular Weight | 656.19 |
| CAS Numbers | 2700286-66-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | ClC1=C(C=2N=C(NCC3=CC(F)=CC=C3)C=CC2)C=C(N[C@H]4CC[C@H](NC(=O)C5=CC=C(NC(C=CCN(C)C)=O)C=C5)CC4)N=C1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Kuang Z, et al. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Br J Cancer. 2023 Oct 26.